Partnering With Japanese Pharmaceutical Companies

For those of you who were unable to attend the seminar or if you'd like to review the content, the webcast is now available.

Takeda's $1 Billion acquisition of Japanese rights to Amgen's drugs is the latest high profile transaction between a U.S. biotech and a Japanese pharmaceutical company.

Over the past several years, transactions with Japanese pharmaceutical companies have provided access to new markets, financial capital, and intellectual property rights for compounds for development.

Our panel of experts will discuss how to initiate, negotiate and execute a successful relationship with a Japanese pharmaceutical company.

Topics Include:

Overview of Market Trends

Anatomy of the Amgen/Takeda Deal

Structuring Deals with Japanese Pharmaceutical Companies

What Makes for a Successful Negotiation Between U.S. and Japanese Companies

To view this webinar, please click here.

Because of the generality of this update, the information provided...